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ScienceDirectIn the airways, arginase and NOS compete for the common
substrate L-arginine. In chronic airway diseases, such as
asthma and COPD, elevated arginase expression contributes
to airway contractility, hyperresponsiveness, inflammation and
remodeling. The disrupted L-arginine homeostasis, through
changes in arginase and NOS expression and activity, does not
only play a central role in the development of various
airways diseases such as asthma or COPD. It possibly also
affects L-arginine homeostasis throughout the body
contributing to the emergence of co-morbidities. This
review focusses on the role of arginase, NOS and ADMA in
co-morbidities of asthma and COPD and speculates on their
possible connection.
Addresses
1Department of Molecular Pharmacology, University of Groningen,
Antonius Deusinglaan 1 (XB10), 9713 AV Groningen, The Netherlands
2Groningen Research Institute for Asthma and COPD (GRIAC),
University of Groningen, Groningen, The Netherlands
Corresponding author: Gosens, Reinoud (r.gosens@rug.nl)
Current Opinion in Pharmacology 2018, 40:126–133
This review comes from a themed issue on Respiratory
Edited by Mario Cazzola and Maria Gabriella Matera
https://doi.org/10.1016/j.coph.2018.04.010
1471-4892/ã 2018 Published by Elsevier Ltd.
Introduction
Arginase catalyzes the reaction in which L-arginine is
converted to L-ornithine and urea. In humans, two argi-
nase isoenzymes have been identified, arginase 1 and
arginase 2, that differ in cellular location and tissue
distribution [1]. Both arginase enzymes are constitutively
expressed in the airways. The cytosolic arginase 1 and
mitochondrial arginase 2 can particularly be found in
airway endothelial cells, epithelial cells, fibroblasts
and macrophages [2]. Furthermore, the expression of
both enzymes can be induced in airway smooth muscle
cells [3,4].Current Opinion in Pharmacology 2018, 40:126–133 Downstream metabolism of L-ornithine leads to the for-
mation of polyamines and L-proline, which are involved in
cell proliferation and differentiation, and collagen pro-
duction, respectively [1,5]. Next to the effects of meta-
bolic products of arginases, many biological effects of the
enzymes are related to their competition with nitric oxide
synthases (NOS) for the common substrate L-arginine.
Three distinct NOS enzymes are expressed in mammals;
endothelial NOS (eNOS), neuronal NOS (nNOS) and
inducible NOS (iNOS). As eNOS and nNOS are consti-
tutively expressed in the airway epithelium, in inhibitory
nonadrenergic noncholinergic neurons (nNOS) and air-
way vascular endothelial cells (eNOS), they are also
referred to as constitutive NOS (cNOS). All NOS iso-
enzymes use L-arginine for the formation of nitric oxide
(NO) and L-citrulline. Increases in intracellular calcium
concentrations, through the action of agonists or mem-
brane depolarization, trigger cNOS to produce relatively
low amounts of NO. iNOS is particularly expressed in
epithelial cells and macrophages during inflammation. In
contrast to cNOS, iNOS produces large amounts of NO
and enzyme activation is dependent on changes gene
expression, among others induced by proinflammatory
cytokines [6]. Furthermore, when L-arginine levels are
low, for example due to elevated arginase activity, NOS is
uncoupled and superoxide is formed. Superoxide rapidly
reacts with NO to form peroxynitrite, often leading to
detrimental effects in the tissue by nitration of tyrosine
residues [7].
The arginase and NOS pathways may interact at different
levels (Figure 1). This could be through competition
for L-arginine, inhibition of arginase by the intermediate
NOS metabolite Nv-hydroxy-L-arginine and through
L-ornithine that causes feedback inhibition of arginase
and inhibition of L-arginine uptake by cells producing
NO. Next to arginase, NOS and their metabolic products,
also methylated arginines such as the arginine derivatives
asymmetric dimethylarginine (ADMA) and symmetric
dimethylarginine (SDMA) can greatly influence L-argi-
nine homeostasis [8]. ADMA and its inactive stereoiso-
mer SDMA are primarily formed as byproducts during
the degradation of methylated arginine containing
residues. Furthermore, small amounts of ADMA may
be produced from free arginine directly [9]. Whereas
ADMA serves as an endogenous competitive inhibitor
of NOS, SDMA influences NO synthesis by competing
with arginine and other methylated arginines for cellular
transport [8].www.sciencedirect.com
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The interactive role of arginase, NOS and ADMA in L-arginine homeostasis. Arginase and NOS compete for their common substrate L-arginine.
Arginase converts L-arginine to urea and L-ornithine. Downstream conversion of L-ornithine leads to the production of polyamines and L-proline,
that contribute to cell proliferation and differentiation, and collagen formation, respectively. Also, L-ornithine inhibits arginase activity. During
conversion of L-arginine to NO and L-citrulline by NOS, the endogenous arginase inhibitor NOHA is formed. NO induces smooth muscle relaxation,
a decrease in inflammation and forms metabolites in the airway. At low L-arginine levels, NOS is uncoupled and O2
 is formed, which reacts
rapidly with NO to form ONOO. AMDA and SDMA are formed by degradation of methylated arginine containing proteins. ADMA may also be
formed from free L-arginine. ADMA serves as an endogenous antagonist of NOS. ADMA, asymmetric dimethylarginine; NO, nitric oxide; NOHA,
Nv-hydroxy-L-arginine; NOS, nitric oxide synthases; O2
, superoxide; ONOO, peroxynitrite; SDMA, symmetric dimethylarginine.We and others previously showed that an increased argi-
nase activity in the airway contributes to airway obstruc-
tion and hyperresponsiveness, by reducing the available
substrate for cNOS and iNOS [10]. As a result, production
of bronchodilatory NO is decreased and superoxides are
formed, which react with NO to form peroxynitrite,
thereby enhancing airway contraction and inflammation.
Furthermore, elevated airway arginase activity leads to
increased L-ornithine production. Which potentially con-
tributes to airway remodeling by increased cell prolifera-
tion and collagen formation [10,11]. The disrupted L-
arginine homeostasis, through changes in arginase and
NOS expression and activity, does not only play a central
role in the development of various airways diseases such
as asthma or COPD. It possibly also affects L-arginine
homeostasis throughout the body contributing to the
emergence of co-morbidities. This review focusses on
the role of arginase and NOS in co-morbidities of asthma
and COPD (Table 1) and speculates on their possible
connection.www.sciencedirect.com Asthma
The chronic airway inflammatory disease asthma is asso-
ciated with enhanced levels of exhaled NO generated by
iNOS in the airway epithelium [12]. In asthmatic patients
local and systemic changes in iNOS, peroxynitrite, argi-
nase, ADMA and arginine levels have been observed and
are associated with i.a. lung function and asthma severity
[5,10,13]. In support, gene association studies in asth-
matic patients [14] and different animal models of allergic
asthma [15,16] show a key role for arginase in different
aspects of the disease.
Allergic rhinitis is a frequent co-morbidity of asthma [17].
Allergic rhinitis patients show increased nasal arginase
and iNOS expression [18,19], and changes in nitrite/
nitrate and nitrite serum levels during symptomatic per-
iods [20,21]. Furthermore, peroxynitrite plays a likely role
in nasal blockage after allergen encounter [22]. Interest-
ingly, the role of arginase in allergic rhinitis has not much
been studied. Treatment of allergic rhinitis patients withCurrent Opinion in Pharmacology 2018, 40:126–133
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Table 1
Changes in L-arginine regulation by arginase, NOS and ADMA in co-morbidities of asthma and COPD
Co-morbidity Changes in L-arginine regulation
Allergic dermatitis "iNOS and eNOS in dermal lesions [43,45]; iNOS induces a-MSH [44]; #arginase activity in skin
granulocytes and plasma [42].
Allergic rhinitis In nasal mucosa: "iNOS [19]; "arginase 1 and 2 [18]. In serum: "arginase, #nitrite and nitrite/nitrate [20,21].
Role for ONOO in nasal blockage [22].
Cardiovascular disease Hypoxia induced "arginase expression [51,52,54] leads to #cardiac contractility and recovery and
"remodeling [39,53,55]. Arginase 1 enhances stability of atherosclerotic plaques [57].
Cerebrovascular disease "Arginase expression leads to vessel narrowing [57]; #recovery after stroke [58]; "AMDA expression leads
to #cerebral blood flow and "chance of stroke [59–61].
Lung cancer "Arginase 1 expression in myeloid cells and tumor samples [75], possibly leads to "tumor proliferation
[73,79] by "polyamine production or #NO; arginase as marker of T-cell induced tolerance [72].
Metabolic syndrome Cytokines and hypoxia induce: "arginase, "ADMA; and #systemic NO [59].
Muscle wasting "Ornithine production, possibly by "arginase activity, leads to #creatine production [80]. M2 macrophages
promote muscle proliferation [81].
Obesity In blood and liver "arginase and #NO [64,65,82]. In adipose tissue: p38/MAPK induces eNOS uncoupling
[83], "arginase and L-arginine deficiency [66]; "adipose tissue m1 macrophage infiltration and
inflammation [69,84].
Obstructive sleep apnea syndrome In serum: "arginase activity and #NO levels [37,38]; "plasma NO after treatment [37,41].
Osteoporosis "Arginase expression and activity in bone and BMSCs [70].
Psychological diseases Major depression: "arginase serum activity [25]; # platelet NOS activity and plasma NO metabolites [27];
"ADMA concentration [26]. Chronic stress: "iNOS and nNOS in neocortex and hippocampus [29].
Respiratory infection "Arginase in lung myeloid cells leads to "pathogen survival [31,32]. "iNOS shortly after infection (by Th1
cells); "NO, NO metabolites and ADMA [33–35]; conversion of L-citrulline by T-cells leads to "L-arginine
[31].
Type II diabetes Insulin resistance correlated with "ADMA and "arginase [68]. High glucose induces "arginase and #NO
production [70]. Changes in arginase 1 metabolism in macrophages [85].
ADMA, asymmetric dimethylarginine; BMSC, bone marrow stromal cell; eNOS, endothelial NOS; iNOS, inducible NOS; MAPK, mitogen-activated
protein kinase; a-MSH, a-melanocyte-stimulating hormone; NO, nitric oxide; nNOS, neuronal nitric oxide synthase; ONOO, peroxynitrite.the leukotriene antagonist montelukast, leads to
decreased arginase serum levels compared to the control
group [23], indicating that in allergic rhinitis, arginase
may be affected by mast-cell mediator release, leading to
a reduced bioavailability of L-arginine for NOS.
Psychological disorders such as depression and anxiety
are important co-morbidities of both asthma and COPD
[17,24]. Major depressed patients show a positive corre-
lation between arginase activity and disease severity [25]
and elevated ADMA and decreased SDMA concentration
[26]. A significant decrease in arginase levels, an increase
in L-arginine/ADMA ration and a trend for increased
global arginine bioavailability is observed after first
improvement at hospital discharge [26]. In addition,
patients with major depression have lower levels of plate-
let NOS activity and NO metabolites in plasma [27].
Antidepressants have normalizing effects on plasma NO
levels [28]. Several studies have looked into the effect of
NOS isoenzymes and inhibition on various brain areas
during stress, however these show contrasting results [29].
After viral and bacterial respiratory infection, common
causes of asthma exacerbation [30], toll like receptor
stimulation upregulates arginase in lung myeloid cells
[31,32]. In response, iNOS is upregulated in lung
macrophages and polymorphonuclear leukocytes shortlyCurrent Opinion in Pharmacology 2018, 40:126–133 after infection, leading to an increase in NO production,
NO metabolites and ADMA levels [33–35] promoting
inflammation. T-cells can replenish L-arginine levels
through the conversion of L-citrulline [31], thereby
supporting the anti-viral or anti-bacterial response. Inhi-
bition of arginase with 2(S)-amino-6-boronohexanoic acid
(ABH), leads to a similar increase in L-arginine [35].
Nasal obstruction, an increased upper airway collapsibil-
ity and a decrease in pharyngeal cross-sectional area in
asthma patients can promote symptoms of obstructive
sleep apnea syndrome (OSAS) [36]. In OSAS patients,
serum NO levels are reduced compared to control sub-
jects [37,38]. In line, serum arginase activity is increased
[38]. This might be induced by intermittent hypoxia that
can also cause upregulation of pulmonary arginase and
pulmonary arterial hypertension [39]. Moreover, concen-
trations of ADMA are found to be increased [40]. Two
independent studies showed that, plasma NO levels can
be increased by treatment with continuous positive air-
way pressure [37,41]. Whether OSAS treatment also
decreases arginase activity has not been investigated.
In contrast, granulocytes and plasma of allergic dermatitis
patients show a decreased arginase activity compared to
controls [42]. iNOS expression is found to be upregulated
in skin biopsies of allergic dermatitis patients [43]. Thiswww.sciencedirect.com
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of allergic dermatitis, where it is shown that iNOS possi-
bly induces a-melanocyte-stimulating hormone, leading
to exacerbation of symptoms [44] and an increase in
protein-bound nitrotyrosine in eosinophils in skin lesions
due to a disrupted NO-balance [45].
COPD
As in asthma, also in COPD, increased expression of
arginase has been reported, and tobacco smoke may
increase expression of arginase in human subjects
[46,47]. Increased ADMA levels have also been reported
in COPD, and both the increased expression of arginase
and ADMA contribute to remodeling and inflammation,
via both NO-dependent and NO-independent pathways
[48,49,50]. Accordingly, arginase inhibition protects
against the development of COPD-like inflammation
and remodeling in a guinea pig model of COPD [49].
Inhibition of NO production appears to not only regulate
local airway inflammation, remodeling and reactivity but
is a key regulatory mechanism in cardiovascular changes
in COPD as well. Local hypoxia in tissues promotes
arginase activity, and represses vasodilating NO produc-
tion [51,52]. In the lung, this mechanism contributes to
pulmonary hypertension and arginase inhibition protects
against the development of pulmonary hypertension and
right cardiac remodeling [39,49]. Likewise, hypoxia in left
heart failure drives arginase expression by endothelial
cells, which plays a clear role in repressing cardiac con-
tractility and recovery from ischemia [53,54]. Accordingly,
inhibition of arginase promotes cardiac contractility and
improves cardioprotection after injury [55].
Such a mechanism may also contribute to cerebrovascular
disease, which is often found as a co-morbidity in patients
with COPD [24]. NO is critical in blood flow regulation in
the brain [56]. Therefore, increased arginase expression
may lead to vasoconstriction, increasing susceptibility to
stroke [57]. In support, arginase 2 deficient mice have
improved cerebral blood flow after brain injury [58]. In
addition, ADMA is considered a prime biomarker and
driver of impaired cerebral blood flow and stroke [59–61].
Though not directly related to arginase, ADMA expres-
sion is increased in smokers and shunts arginine to the
arginase pathway [50], providing a clear mechanistic
link between increases in ADMA and arginase activity.
Surprisingly little data is available on pharmacological
arginase inhibition and its impact on cerebrovascular
disease, although clearly such studies would be of con-
siderable interest.
In COPD and, as indicated above, also in asthma, several
metabolic changes occur that impact on systemic co-
morbidities in COPD such as muscle wasting, osteoporo-
sis and type II diabetes [17,24]. It is not fully clear how
changes in arginase expression in COPD contribute towww.sciencedirect.com each of these co-morbidities specifically, although general
relationships between arginase and nitric oxide metabo-
lism on the one hand and muscle wasting, osteoporosis
and type II diabetes have been reported. Tumor necrosis
factor (TNF) driven nuclear factor-kB activation under-
lies muscle wasting [62] and is inhibited by NO mediated
S-nitrosylation of p65 and inhibitor of NF-kB kinase [63].
Increased arginase activity in COPD may suppress this,
leading to enhanced p65 activation. De-repression of NO-
mediated anti-inflammatory effects and endothelial cell
function due to elevated arginase activity may also play a
role in fatty acid driven changes in insulin sensitivity and
obesity [64]. Thus, increased expression of arginase has
been reported in obese subjects in comparison to normal
weight subjects [51,65] and arginase overexpression has
been shown to drive eNOS uncoupling in mice aortas in
response to overweight [66]. Furthermore, arginase inhi-
bition restores endothelial dysfunction, hepatic abnor-
malities and adipose tissue inflammation (interleukin-6,
TNF-a, M1 macrophage counts) [67,68,69] in animal
models. Arginase is also abundantly expressed in bone,
and streptozocin-induced diabetes was associated with
reductions in bone mass and bone mineral density, both
of which could be prevented by the arginase inhibitor
ABH [70].
Lung cancer is a co-morbidity of COPD with a major role
for arginase. Arginase expression is elevated in non-small
cell lung cancer and drives proliferation by tumor cells
and tumor associated fibroblasts, possibly via polyamine
production or by lowering vasodilating NO, facilitating
hypoxia that promotes cancer stem cell survival [71].
Arginase is also a marker of myeloid derived suppressor
cells that are anti-inflammatory and repress cytotoxic T-
cell responses [72]. In T-cell biology, arginase therefore
promotes tolerance and arginase inhibition boosts anti-
tumor T-cell activity [73,74,75].
Concluding remarks
It is clear that a disordered L-arginine homeostasis by
changes in arginase, NOS and ADMA activity and expres-
sion, is not only vital in the chronic airway diseases,
asthma and COPD, but also seems to play an important
role in many co-morbidities. Unknown, however, is
whether L-arginine disbalance in the lung systemically
affects other organs, thereby contributing to the develop-
ment of co-morbidities. Moreover, it is not clear in how far
altered L-arginine metabolism in systemic comorbidities
may contribute to the severity of asthma and COPD. In
the same line of reasoning, it is also largely unknown if
restoring L-arginine-balance in the airways, for example
by using arginase inhibitors, will alleviate symptoms of
co-morbidities and vice versa. Remarkably, we recently
found that the arginase inhibitor ABH inhibited airway
inflammation and remodeling as well as right ventricular
hypertrophy in a guinea pig model of COPD [49].Current Opinion in Pharmacology 2018, 40:126–133
130 RespiratoryCurrently, lung diseases are preferably treated locally by
inhalation of nebulized drugs. In this way, low doses of
drugs can be used and side-effects are reduced. In animal
models of asthma and COPD, both systemic [76] and local
treatment with arginase inhibitors lead to an increase in
bioavailable L-arginine and reduced pulmonary symp-
toms [16,49,77]. However, most studies in this area have
focused on the organ of interest instead of systemic
effects of arginase inhibition. As with all treatments,
caution should be paid to potential side-effects occurring
during the use of arginase inhibitors, particularly with
regard to ammonia detoxification in the liver. However,
short-term, as well as long-term systemic treatment in
animal models of hypertension and atherosclerosis did not
show any toxic side-effects or induction of a compensa-
tory enzyme upregulation [78]. Naturally, each co-mor-
bidity requires a different approach in treatment. Never-
theless, it would be beneficial when possible treatment of
asthma or COPD by arginase inhibitors, or other drugs
interfering with L-arginine metabolism, could also leads
to relief of symptoms in other organs.
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